HilleVax Taps Sean McLoughlin as Chief Operating Officer
18 Janvier 2024 - 1:49PM
Dow Jones News
By Ben Glickman
HilleVax on Thursday named Sean McLoughlin as the vaccine
developer's next operating chief.
The Boston-based biopharmaceutical company said that co-founder
and current COO Aditya Kohli will become chief business officer as
part of a planned transition.
McLoughlin, 52, recently served as global vaccine
commercialization lead, RSV at GSK. He has held various roles at
GSK over 25 years with the company.
McLoughlin will receive an annual base salary of $450,000, with
an annual target bonus of 45% of his salary and a sign-on bonus of
$200,000.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 07:34 ET (12:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
HilleVax (NASDAQ:HLVX)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
HilleVax (NASDAQ:HLVX)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
